Changing the policy for intermittent preventive treatment with sulfadoxine–pyrimethamine during pregnancy in Malawi by Chikondi A. Mwendera et al.
Mwendera et al. Malar J  (2017) 16:84 
DOI 10.1186/s12936-017-1736-9
CASE STUDY
Changing the policy for intermittent 
preventive treatment with sulfadoxine–
pyrimethamine during pregnancy in Malawi
Chikondi A. Mwendera1, Christiaan de Jager1*, Herbert Longwe2, Kamija Phiri3, Charles Hongoro1,4 
and Clifford M. Mutero1,5
Abstract 
Background: The growing resistance of Plasmodium falciparum to sulfadoxine–pyrimethamine (SP) treatment for 
uncomplicated malaria led to a recommendation by the World Health Organization for the use of artemisinin-based 
combination therapy. Inevitably, concerns were also raised surrounding the use of SP for intermittent prevention 
treatment of malaria during pregnancy (IPTp) amidst the lack of alternative drugs. Malawi was the first country to 
adopt intermittent prevention treatment with SP in 1993, and updated in 2013. This case study examines the policy 
updating process and the contribution of research and key stakeholders to this process. The findings support the 
development of a malaria research-to-policy framework in Malawi.
Methods: Documents and evidence published from 1993 to 2012 were systematically reviewed in addition to key 
informant interviews.
Results: The online search identified 170 potential publications, of which eight from Malawi met the inclusion crite-
ria. Two published studies from Malawi were instrumental in the WHO policy recommendation which in turn led to 
the updating of national policies. The updated policy indicates that more than two SP doses, as informed by research, 
overcome the challenges of the first policy of two SP doses only because of ineffectiveness by P. falciparum resistance 
and the global lack of replacement drugs to SP for IPTp.
Conclusion: International WHO recommendations facilitated a smooth policy change driven by motivated local 
leadership with technical and financial support from development partners. Policy development and implementation 
should include key stakeholders and use local malaria research in a research-to-policy framework.
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Background
The resistance of the malaria parasite to anti-malarial 
drugs has led to expensive policy changes in many coun-
tries causing strain on available resources [1]. Although 
the World Health Organization (WHO) is instrumental 
in guiding health policy development, contextual factors 
unique to different countries need to be assessed before 
adopting and implementing these recommendations [2].
Policy development is a tedious process that requires 
an understanding of the institutional and individual 
actors and of the context in which the process occurs 
[3]. Walt and Gilson [4] described this relationship when 
they developed a health policy framework that explores 
the context, content, and processes in which actors 
are engaged. Andersen [5] developed a framework for 
understanding the policy process incorporating problem 
identification, agenda setting, policy formulation, policy 
adoption, policy implementation and policy evaluation.
Malawi established its National Malaria Control Pro-
gramme (NMCP) in 1984 [6]. The NMCP based their first 
five-year implementation plan (1985–1989) on WHO 
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recommendations for malaria control in areas with 
proven chloroquine (CQ) resistance in Africa [7]. One 
of its policies was to provide CQ chemoprophylaxis to 
special groups of individuals including pregnant women. 
In response to the growing evidence of CQ resistance, 
studies assessed alternative drugs to replace CQ. Malawi 
invested tremendously in research on malaria in preg-
nancy and became the first country to adopt intermittent 
preventive treatment in pregnancy with sulfadoxine–
pyrimethamine (IPTp-SP) in 1993 [8, 9]. The policy rec-
ommended that pregnant women should receive two 
doses during pregnancy with the first dose being given 
at the first antenatal visit after the first trimester of preg-
nancy (typically 16th to 22nd week of gestation) and 
the second dose at the beginning of the third trimester 
(between 28 and 34 weeks of gestation) [10]. Over time, 
growing P. falciparum resistance to SP for the treatment 
of uncomplicated malaria led to the WHO recommenda-
tion of switching to artemisinin-based combination ther-
apy (ACT) [11] and related concerns were raised about 
the efficacy of SP for IPTp. The WHO convened an Evi-
dence Review Group (ERG) on IPTp-SP in 2012 which 
reviewed various research evidence relevant to updating 
the IPTp policy. The ERG acknowledged that more than 
two doses of IPTp-SP would be more beneficial than the 
usual two doses that were previously administered [8]. 
The ERG recommended that IPTp-SP be given at each 
antenatal visit, with the first dose given early in the sec-
ond trimester and subsequent doses given at monthly 
intervals up to the time of delivery. Following these rec-
ommendations, in 2013 the NMCP in Malawi adapted 
its IPTp-SP policy by recommending that women should 
receive at least three doses of SP during pregnancy [12].
The process of updating the IPTp-SP policy was exam-
ined with the aim of understanding policy development. 
The role of stakeholders and relevant research evidence 
during the policy development in Malawi was also assessed.
Conceptual framework
This case study forms part of a larger effort to understand 
policy development and the role of relevant research in 
this process in order to develop a framework that can 
facilitate the use of evidence from malaria research for 
policy formulation in Malawi. One important aspect of 
policy analysis is to understand the involvement of stake-
holders and research in the process while considering the 
various factors that govern the need for the policy [13]. 
This study was conceptualized on the premise that differ-
ent factors besides overwhelming evidence may influence 
policy development. The Walt and Gilson policy analysis 
framework [4] stipulates that aside from content analy-
sis, the actors, processes and the context in which policy 
change occurs are required for policy analysis. The policy 
analysis was supplemented by the Andersen’s model of 
policy cycle [5].
Methods
Mixed methods in form of a systematic review of pub-
lished evidence, a review of key documents and key 
informant in-depth interviews (KIIs) were utilized in the 
policy analysis to enable triangulation.
Systematic review
This method aimed to establish the availability of local 
evidence likely to be used in the policy change process. 
Relevant articles were sought by searching the references 
of all reviewed articles. Combinations of the following 
specific key words relating to IPTp-SP were searched 
by using the medical subject heading (MESH) strategy: 
sulfadoxine–pyrimethamine (SP), Fanasil, pyrimeth-
amine drug combination, pregnancy, and Malawi. Arti-
cles published between 1993 and 2012 were searched 
to capture all studies conducted in Malawi related to 
IPTp-SP from inception to the time of the policy update. 
These studies were assumed to provide timely evidence 
and were more likely to be included in the policy devel-
opment process. The following combinations were 
used during the search: (“pregnancy” [MeSH Terms] 
OR “pregnancy” [All Fields]) AND (“fanasil, pyrimeth-
amine drug combination” [Supplementary Concept] OR 
“fanasil, pyrimethamine drug combination” [All Fields] 
OR “sulfadoxine–pyrimethamine” [All Fields]) AND 
(“Malawi” [MeSH Terms] OR “Malawi” [All Fields]) 
AND (“1993/01/01” [PDAT]: “2012/12/31” [PDAT]). We 
searched the MEDLINE (Ovid), PubMed, Scopus and 
Cochrane Library databases.
Selection criteria
From the articles identified by the systematic review 
above, studies selected for analysis were based on the fol-
lowing criteria: (1) conducted in Malawi between 1993 
and 2012; (2) evaluating two doses of IPTp-SP; (3) eval-
uating three or more IPTp-SP doses; (4) assessing two 
versus three or more IPTp-SP doses. The selection was 
limited to studies assessing the optimal response of P. fal-
ciparum infection to IPTp-SP by excluding studies con-
ducted on HIV-positive women. HIV infection reduces 
the ability of a pregnant woman to control the malaria 
infection resulting in a suboptimal response to IPTp-SP 
[14]. Two independent co-authors, CM and HL, judged 
the eligibility of the studies and resolved disagreements 
by consensus.
Document review
Available documents such as reports, circulars, direc-
tive letters and minutes from meetings conducted during 
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the policy development process were sought to provide 
a forum for triangulation, to verify the stakeholders and 
to verify important dates and events throughout the 
process. WHO IPTp policy documents [8, 15] and local 
IPTp-SP policy documents [12] were reviewed to exam-
ine the extent to which they referenced research evidence 
during policy development.
Key informant interviews
KIIs with key stakeholders involved in policy develop-
ment comprising malaria researchers/advisors, policy 
makers, and programme/project coordinators were con-
ducted. Interviewees participated in the policy updating 
process, and their views were considered to capture what 
transpired and general experiences on the change. Purpo-
sive sampling identified key informants. Fifteen individu-
als were identified and interviewed. Six interviewees were 
senior malaria-in-pregnancy researchers and advisors, 
three interviewees were policy makers and six interview-
ees were programme/project coordinators. Table 1 sum-
marizes the experience, expertise and role played by each 
key informant (KI) during the policy changes.
The principal investigator conducted all the interviews, 
probing and exploring in-depth issues based on the con-
ceptual framework of the study. The interviews were con-
ducted in English using a semi-structured interview tool.
Themes covered in the in‑depth interviews
The participants were asked to narrate their memories of 
the policy process by contemplating the question: “Can 
you please describe the process by which the IPTp-SP pol-
icy change occurred in Malawi?”
Interviews covered specific themes that included: (1) 
context in which the policy occurred; (2) opportunities 
during the policy process; (3) challenges encountered 
during the policy process and (4) lessons learned.
Data management and analysis
The recordings were transcribed and coded based on the 
themes, and the software Nvivo 11 was used to organize 
the data, while verbatim quotes illustrated concepts, sup-
ported conclusions and brought reality to the situation. 
The Giorgi’s phenomenological approach, which focuses 
on the experiences of participants with shared life expe-
riences, was used. This approach documents the find-
ings from the interviewee’s point of view, collecting their 
descriptions of their lived world on the interpretation of 
the meaning of the described phenomena [16].
Results
Systematic review
One hundred and seventy potential publications were 
identified using database searches of which eight publica-
tions from Malawi were selected using the inclusion cri-
teria and subsequently reviewed (Fig. 1).
Description of the publications
Eight studies that met the inclusion criteria were 
reviewed (Table  2). Verhoeff et  al. [17] measured the 
parasite prevalence in mothers who received one, two, 
or three SP doses during pregnancy and the associated 
incidence of low birth weight (LBW) in infants. Although 
there was no significant difference in peripheral or pla-
cental blood parasite prevalence, the mean birthweights 
Table 1 Details of  key informants (KIs) involved in  the policy update for  intermittent preventative treatment dur-
ing pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) for malaria in Malawi
KI Sex Expertise Experience Role
1 Male Malaria epidemiologist Over 15 years in malaria research Researcher/advisor
2 Male Medical epidemiologist Over 10 years in malaria research Researcher/advisor
3 Female Malaria epidemiologist Over 30 years in malaria research Researcher/advisor
4 Male Clinician and malaria epidemiologist Over 40 years in malaria research Researcher/advisor
5 Male Malaria epidemiologist Over 10 years malaria research Researcher/advisor
6 Male Senior malaria scientist Over 40 years in malaria research Researcher/advisor
7 Female Clinical epidemiologist 6 years Policy maker
8 Male Malaria in pregnancy coordinator Over 5 years in malaria research Policy maker
9 Male Chief of health services Five years Policy maker
10 Female Malaria in pregnancy coordinator Over 5 years in malaria research Programme/project coordinator
11 Male Malaria advisor 15 years Programme/project coordinator
12 Male Malaria advisor 5 years Programme/project coordinator
13 Male Policy development and analysist 4 years Programme/project coordinator
14 Male Malaria advisor 5 years Programme/project coordinator
15 Male Malaria program specialist 20 years Programme/project coordinator
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of infants were higher, resulting in a decrease of LBW 
babies born to mothers that received two or more SP 
doses. Taylor et al. [18] explored the link between IPTp-
SP, the presence of resistant parasite at delivery and mul-
tiple measures of adverse delivery outcome. Receiving 
SP as IPTp did not raise pregnancy-associated malaria 
despite increasing prevalence and fixation of SP-resist-
ant P. falciparum. Although LBW prevalence was lower 
(11.8%) in the full IPTp group than in the suboptimal 
group (P  =  0.48), the difference was not significant. 
Taylor et  al. [18] recommended the modified regimen 
of IPTp-SP for comprehensive antenatal care. Rogerson 
et al. [19] assessed the relationship between the number 
of IPTp-SP doses and various health indicators. Placental 
malaria prevalence decreased from 31.9%, in women who 
did not receive SP, to 22.8% in women with ≥2 SP-doses, 
while LBW prevalence decreased from 23% (no IPT) to 
10.3% (IPTp-SP) in the two groups of women. Rogerson 
et al. [19] recommended that IPTp-SP should be contin-
ued based on the positive impact, but that researchers 
continuously evaluate treatment. Filler et al. [14] assessed 
the efficacy of monthly SP compared to the two doses of 
SP in preventing placental malaria in both HIV positive 
and negative women. HIV negative women who received 
a monthly dose of SP had a lower (2.3%) incidence of 
placental malaria compared to women who received two 
doses (6.3%). Filler et al. [14] recommended that areas of 
intense falciparum transmission should adopt a monthly 
IPTp-SP regimen. This study was included in the meta-
analysis that led to the WHO policy recommendation 
[15, 20].
Several similar studies have assessed the efficacy of 
the monthly SP dose. Luntamo et  al. [21] compared 
the effect of monthly SP, or monthly SP and two doses 
of azithromycin (AZI-SP) to the standard 2-SP regi-
men in preventing preterm deliveries and LBW. Pre-
term incidence was 17.9% in controls (2-SP), 15.4% in 
the monthly group (P =  0.32) and 11.8% in the AZI-SP 
group (P = 0.01). There was a lower risk of LBW in the 
AZI-SP group (0.61, P = 0.02) and the monthly SP group 
(0.71, P = 0.71) compared to the control group. Luntamo 
et  al. [21] concluded that AZI-SP reduces the incidence 
of preterm delivery and LBW under certain conditions. 
Luntamo et  al. [22] compared the effect of monthly SP, 
or monthly SP and two doses of azithromycin (AZI-SP) 
and a standard 2-SP dose (control) on malaria at delivery. 
HIV-negative women that received a monthly dose of 
SP (0.26, P < 0.0001) and those that received the AZI-SP 
regimen (0.249, P < 0.0001) had a significantly lower risk 
of malaria compared to the control group. Luntamo et al. 
Fig. 1 A flow chart of the selection process for studies reviewed
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[22] recommended that frequency of SP doses during 
pregnancy should be increased; these recommendations 
were included in the meta-analysis leading to amended 
WHO policy recommendations [15, 20]. Luntamo et  al. 
[23] compared the effect of monthly SP, or AZI-SP and 
a standard 2-SP dose (control) on foetal and neonatal 
growth. Pregnant women who received monthly SP had 
babies with heavier mean birthweights that were taller at 
four weeks of age, and the addition of azithromycin fur-
ther increased the benefits in reducing growth faltering. 
Gutman et al. [24]. assessed the effectiveness of IPTp-SP 
on placental infection and composite birth outcomes. 
Their findings showed that IPTp-SP was associated with 
a dose-dependent protective effect on composite birth 
outcomes but did not reduce the frequency of placen-
tal infection. They recommended that IPTp-SP be given 
while exploring alternative strategies and drugs.
Document review
Policy documents were examined to assess how research 
evidence was used and included in WHO documents [8, 
15] and the local treatment policy [12]. The WHO docu-
ments used a variety of evidence from across the globe 
upon which they based their policy formulation. Evi-
dence from Malawi was instrumental in agenda setting 
[9, 25] and policy development [14, 18, 19, 21–23, 26]. 
The local treatment policy document did not have a for-
mal reference section which hampered the assessment of 
used evidence. However, the authors of the policy docu-
ment acknowledged the importance of the WHO recom-
mendations during its development.
Stakeholders and their roles during the IPTp‑SP policy 
change
The Ministry of Health (MOH) (represented by the 
NMCP and the Reproductive Health Directorate (RHD)), 
the National Malaria Advisory Committee (NMAC); 
Malaria Care, Clinton Health Access Initiative (CHAI), 
WHO; Support for Service Delivery Integration-Services 
(SSDI-services), malaria researchers, and PMI/USAID 
were primary stakeholders in the policy change process. 
Stakeholders gave technical advice, developed guidelines, 
reviewed and edited guidelines, trained health workers, 
implemented policies in health facilities, and provided 
financial support for conferences and other resources 
(Table 3).
The process of change
The policy change began in July 2012 when the WHO 
ERG made a recommendation to the Malaria Policy 
Advisory Committee (MPAC) for an interim policy on 
IPTp-SP [8]. The recommendation was adopted after 
an assessment of a systematic review and meta-analysis 
[20]. The ERG based their recommendations on find-
ings that associated three or more SP doses for IPTp 
with increased mean birth weight and reduced risk of 
LBW births. Based on the reviewed evidence, the ERG 
recommended IPTp-SP for all pregnant women with the 
first dose administered at antenatal visits as early as pos-
sible in the second trimester, and the subsequent doses 
spaced no less than four weeks apart up to the time of 
delivery [8]. Following this meeting in October 2012, 
WHO updated its IPTp-SP policy, and in April 2013 a 
policy brief was issued to support dissemination and urge 
national health authorities to adopt and implement the 
new recommendations.
Steps for IPTp‑SP policy change in Malawi
Based on emerging literature and WHO recommen-
dations, the NMCP updated malaria treatment guide-
lines that incorporated rectal and injectable artesunate, 
malaria rapid diagnostic tests (RDTs) for quick diagnosis 
of uncomplicated malaria, and the new IPTp-SP policy. 
Malawian policy makers took the opportunity to adapt 
the IPTp-SP policy given the challenges experienced 
during the implementation of the previous policy. The 
implementation of the previous policy was hampered by 
health workers’ confusion surrounding the delivery of the 
second dose of SP [27]. The updated WHO recommenda-
tions do not specify the number of doses, but highlight 
that SP should be provided to pregnant women at each 
scheduled antenatal visit after the first trimester up until 
the time of delivery. The adapted Malawi IPTp-SP policy 
indicates that pregnant women should receive at least 
three doses of SP after the first trimester and with the last 
dose given close to the time of delivery. The new recom-
mendation was strategically planned to coincide with the 
WHO initiative of integrating IPTp-SP into focused ante-
natal care (FANC) services that recommend at least four 
scheduled antenatal care visits [15].
In May 2013, the NMAC convened to vet the treatment 
guidelines before the Minister of Health and the Secre-
tary for Health approved the new guidelines. Initially, 
Malaria in Pregnancy (MIP) formed part of the treatment 
guidelines in Malawi, and it was deemed vital to isolate 
and develop specific guidelines for MIP. In June 2013, a 
group comprising of the NMCP, RHD, and PMI/USAID, 
coordinated by the SSDI-services, convened for one week 
to develop MIP guidelines and revise the MIP training 
manual for health workers following the WHO recom-
mendations. The guidelines were approved in July 2013 
[12].
From October to November 2013, two Trainer of 
Trainers (TOTs) workshops were conducted in the 
northern and central eastern zones of the country to 
orient TOTs on the updated malaria case management 
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guidelines and new IPTp-SP policy. The TOTs were 
immediately required to roll out training sessions for 
other health workers in their work places. Despite this 
requirement, training sessions for health workers only 
commenced in August 2014. The delay in transition was 
due to a change in the per diem policy by  the govern-
ment through the Office of President and Cabinet (OPC) 
on all Developing Partner (DP) programmes in Malawi. 
The per diem policy changed regarding direct payments 
to service providers for costs such as accommodation. 
Participants did not receive sitting allowances and were 
not paid if they conducted duties for which they received 
a salary during the training session. These adjustments 
meant that participants were not able to pay for necessi-
ties if they travelled to different training venues. Logisti-
cal issues were resolved by conducting training sessions 
in areas where most of the participants were situated, and 
the new policy was implemented in August 2014. Evalu-
ation of the new IPTp-SP policy is yet to be conducted. 
Figure 2 illustrates the timeline of policy change process, 
and the roles played by stakeholders based on Andersen’s 
model of policy change [5].
Context of policy change
In 2007, Malawi changed its treatment policy for uncom-
plicated malaria from SP to artemether–lumefantrine. 
The change of drug regimen was complicated as it 
attracted many activities which required approval by the 
Ministry of Health. The new treatment guidelines for 
IPTp-SP were introduced in 2013 and was uncomplicated 
by comparison. Updating the policy did not draw any 
official launch since it was approved along with the treat-
ment policy. This offered an enabling environment for a 
smooth transition of the IPTp-SP policy change as nar-
rated below:
“In fact there is no need for launching when it’s a 
revised policy but if it’s a new policy that’s when the 
launching comes in” (Programme/Project Coordina-
tor)
The policy update aimed to overcome a flaw of the old 
2-IPTp-SP policy. Health workers were confused about 
the exact time to give the second dose mainly due to 
late antenatal attendance by women leading to the pro-
gramme failing to meet the 80% Roll Back Malaria cov-
erage target [27]. The new policy was adapted to address 
this challenge as highlighted below:
“We noted a big challenge that there was a mis-
understanding in terms of application by the ser-
vice providers because it [the policy] was saying at 
13  weeks give the first dose of SP then the second 
dose at 28  weeks…so people just complied to those 
dates…so if one comes at 18th week or 20th week 
then [they] will not be given SP and who comes at 
32 weeks would not be given the second dose…so the 
previous guidelines made some limitation and that 
was our main challenge for low coverage but this 
policy change to 3 doses or more means that a preg-
Table 3 Summary of activities provided by key stakeholders involved in the policy updating process for intermittent pre-
ventative treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) for malaria in Malawi
NMCP National Malaria Control Programme, RHD Reproductive Health Directorate, SSDI support for service delivery integration, PMI President’s Malaria Initiative, 
USAID United States Agency for International Development, NMAC National Malaria Advisory Committee, CHAI Clinton Health Access Initiative, MOH Ministry of 
Health, WHO World Health Organization
Stakeholder Main responsibility Role in policy change
NMCP Development of malaria policies, and implementation of 
malaria programs
Drafting of guidelines, leading the process, and finalization of guidelines
RHD Implementation of reproductive health services in the 
MOH
Drafting of the guidelines, and policy implementation
SSDI-services Effective integration and delivery of quality services under 
the Malawi Essential Health Package (EHP), and to 
strengthen the national health system in line with the 
National Health Sector Strategic Plan for 2011–2016
Coordination of activities, drafting of guidelines, finalizing, printing, dis-
semination of guidelines, and training of health workers
WHO Provision of technical advice and recommendation Overseeing of the whole process in accordance to WHO recommenda-
tions
PMI/USAID Provision of technical and financial support for the NMCP Provided financial support for all activities and provided technical advice
NMAC Provide expert opinion to the NMCP in policy and pro-
gramme development
Vetting and final approval of the guidelines
Malaria Care Provision of malaria diagnostic and treatment services Training of health workers
CHAI Strengthening of integrated health systems Revision of case management guidelines, training of health workers
Malaria 
researchers
Conducting malaria research to provide evidence and 
guide policy formulation
Provided technical review of evidence and guidelines
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nant woman can get IPTp even after 36 weeks…there 
are no restrictions so that’s one of the advantages”. 
(Programme/Project Coordinator)
The global  lack of an alternative drug  to replace SP 
for IPTp meant that increasing the doses, as stipulated 
by evidence, was the only tangible alternative. The chal-
lenges of coverage (as highlighted above), lack of an 
alternative drug and new evidence on dosage incre-
ment provided an ideal environment for IPTp-SP policy 
change.
“We do not have any other alternative that’s why 
they are recommended that we should just use 3 or 
more doses but studies by College of Medicine are 
underway to explore other drugs”. (Programme/Pro-
ject Coordinator)
Opportunities for smooth policy transition
Participants revealed that the availability of technical and 
funding support from partners (USAID/PMI and SSDI-
services) supported the completion of policy updating pro-
cess. This was acknowledged as follows:
“Funding component and technical support was 
assured by the project…but also PMI who are the 
funders of the project…a malaria section…I think they 
have been very supportive….I think they wanted this to 
succeed as such their pressure made it easier for us to 
move forward”. (Programme/Project Coordinator)
The relatively low cost of SP facilitated smooth policy 
transition. The low cost of SP meant that increasing doses 
would not incur a heavy cost, and that partners were will-
ing to fund the policy implementation.
“SP is frankly pretty [an] inexpensive drug…so we 
can usually cover the entire need for a few hundred 
thousand dollars a year…compared to ACTs and 
RDTs and others”. (Programme/Project Coordinator)
The WHO policy recommendations, based on a robust 
evidence review, also facilitated smooth policy transition. 
Such a consensus makes it easier for countries to adopt as 
stipulated below:
“WHO has also been pushing that we change… and 
the policy brief was backed by a lot of scientific evi-
dence that was done extensively across the globe… so 
Fig. 2 The policy making process, timeline of events and stakeholders involved in the policy updating process for intermittent preventative treat-
ment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) for malaria in Malawi
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that push from these global stakeholders also ena-
bled us to work fast”. (Programme/Project Coordina-
tor)
“Actually we just adapted the WHO guidelines…
revised the malaria treatment guidelines accord-
ingly…that was really straight forward”. (Researcher/
Advisor)
The NMCP, who are the key stakeholders in imple-
menting malaria control interventions in the country, 
had a vested interest in updating the policy. The NMCP 
made all efforts from within the government to adopt and 
implement the policy change. This was confirmed below:
“Overall the National Malaria Control Programme 
who are the mandated programme to look at 
malaria, also had keen interest for this to happen 
and be implemented”. (Programme/Project Coordi-
nator)
The inclusion of relevant stakeholders at the beginning 
of the process of change was key in driving the policy 
update. The inclusion of RHD, who implement IPTp as 
an integrated reproductive health service, was strategic at 
policy implementation stage, as described below:
“I need to point out that the reproductive health 
directorate [as a] key department in malaria in 
pregnancy issues were also very supportive…you 
know we cannot talk of malaria in pregnancy with-
out the reproductive health directorate because [it] 
is a platform that we use to implement IPTp”. (Pro-
gramme/Project Coordinator)
Challenges encountered in the policy process
The NMCP were mandated to develop the new IPTp-
SP as a stand-alone malaria control policy. The previous 
IPTp guidelines were embedded as a component within 
the malaria treatment guidelines. Developing new stand-
alone IPTp-SP guidelines was a cumbersome process that 
had to incorporate information that was previously part 
of the Malaria Treatment guidelines, as describe below:
“But now malaria in pregnancy were embedded in 
malaria case management….. and what was lacking 
in those documents were the detailed health edu-
cation that goes with it…financing, partnership…
all those things were missing because it was only 
considered as a treatment component not necessar-
ily as a strategy…so the challenge was that we had 
to develop [the] guidelines from a scratch”. (Pro-
gramme/Project Coordinator)
Developing separate guidelines meant that health 
workers needed to be reoriented to consider IPTp-SP 
as a preventive strategy and an integrated case manage-
ment tool. As acknowledged by a stakeholder that it was 
also difficult to bring together various stakeholders to 
one gathering and commit their time to developing the 
guidelines:
“To get different stakeholders come together and 
agree on something it takes time because people 
have got a lot of demands on their work…so for them 
also to dedicate their time to this, it’s a little bit of 
time”. (Programme/Project Coordinator)
Orientation of health workers occurred in stages, one 
district at a time. Thus other districts were still imple-
menting the old policy while training was taking place. 
This was partly due to funding partners’ policies to 
release funds in stages. Concerns were raised as below:
“This time around we are conducting cascade train-
ing not as the way we always do, because things 
change, partners change the way of doing business, so 
as we are going down to the districts to do the actual 
trainings it will be a little bit slow because others are 
still using the two dose…….because of the way we are 
implementing due to funders money. But otherwise 
in a nutshell we just believe that by the end of the 
year we [will] have finished and the whole country is 
[will] implement one policy”. (Policy maker)
In addition to this challenge was the delay in training 
health workers due to the change in per diem policy by 
the government on all Developing Partner (DP) pro-
grammes in Malawi.
Lessons learnt during the policy change
Participants highlighted that dedication to the policy 
process is critical, especially government commitment. 
Partners can provide resources but if the MOH as owners 
of health policies are not motivated, the process will face 
challenges. A stakeholder confirmed this:
“The most important element for a policy to be effec-
tively developed, the relevant government depart-
ment should have the interest in that policy and they 
drive the whole process…. the NMCP team were so 
keen to have this done…that’s why we didn’t find a 
lot of problems”. (Programme/Project Coordinator)
Another important factor highlighted by participants 
was the availability of local evidence on which to base 
changes. An advisor revealed that research evidence 
forms the foundation for further policy changes:
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“Normally when we want to effect a policy change 
there must have been a study that was conducted 
or an assessment that was conducted…so that has 
always been the trend in Malawi that we are guided 
by studies”. (Researcher/Advisor)
Participants stressed that resources should be available 
at all stages from policy adoption to implementation to 
achieve smooth policy change, as highlighted below:
“When you are embarking on policy change you 
should have everything available, you should have 
the money for the change, for everything that means 
the drugs themselves, for the guideline change, infor-
mation to the general public because you can have 
the money to do the trainings but if you don’t inform 
the public it is very difficult for them to welcome 
the intervention quickly. So when you have all this 
together the policy change is very smooth”. (Policy 
maker)
Participants acknowledged the significance of involv-
ing relevant stakeholders in the policy process ranging 
from funding partners, policy makers in the MOH, Policy 
implementers, and the public.
Discussion
The reduced efficacy of SP in the treatment of uncompli-
cated malaria led to its replacement with ACT as recom-
mended by WHO [28]. Inevitably, concerns were raised 
about the continued use of SP for IPTp. Following these 
concerns, IPTp-SP was extensively monitored to evaluate 
its use or explore alternative drugs. Recently a study con-
ducted in Malawi proposing intermittent screening and 
treatment with dihydroartemisin–piperaquine (ISTp-DP) 
as an alternative to IPTp-SP did not show superiority in 
both parasite clearance and birth outcomes. Thus it rec-
ommended continued use of SP for IPTp [29]. Whilst 
alternative drugs or strategies for IPTp have not yet been 
found, evaluations of IPTp-SP have revealed that giving 
SP to all pregnant women at each antenatal care visit 
from early in the second trimester, with subsequent doses 
spaced four weeks apart up to the time of delivery, is 
beneficial for birth outcomes [8]. Concerns of increased 
doses of SP for IPTp were raised on the uptake of folic 
acid and iron during pregnancy because of SP is a folate 
antagonist. However, evidence has shown that there is no 
interference with SP when the right doses of 30–60 mg of 
element iron plus 0.4 mg/day folic acid supplementation 
are administered [8, 30].
Comprehensive studies conducted in Malawi have 
contributed to the body of knowledge on IPTp and have 
informed local and international IPTp policies. Upon 
implementation of the first global IPTp-SP policy [6], 
Malawi immediately started monitoring the policy and 
confirmed the safety of SP in IPTp and established that 
multiple doses of SP during pregnancy led to a highly 
significant reduction in the incidence of LBW [17]. The 
two SP dose regimen remained unchanged despite these 
results. Increased P. falciparum resistance to SP in the 
treatment of uncomplicated malaria led to similar con-
cerns regarding the use of SP in IPTp. Several studies 
monitored the effects of IPTp-SP during pregnancy and 
birth outcomes. These studies revealed the positive out-
comes of IPTp-SP and recommended that more SP doses 
would have further positive results [14, 18, 19, 21–24]. 
Despite this evidence originating in Malawi, IPTp-SP 
policy changes were only made after the amended WHO 
recommendation was released in 2013. The two studies 
conducted in Malawi [14, 21] were included in the meta-
analysis that led to the change in WHO recommenda-
tions [20] which then informed local policy changes. 
Nevertheless, the WHO does not impose recommenda-
tions since countries are at liberty to adopt or adapt them 
as has been the case for Malawi.
The policy review process in Malawi was largely based 
on WHO recommendations [8, 15] which incorporated 
evidence from Malawi for agenda setting [9, 25] and 
policy development [14, 18, 19, 21–23, 26]. The lack of 
references in the local policy document [12] hampered 
the assessment of the degree to which local research was 
consulted [31]. While the availability of evidence is one 
content factor that needs to be considered when making 
a policy [3], the policy process often overlooks actors, 
processes and contextual factors [4]. In Malawi, the 
involvement of the right stakeholders during the policy 
process was strategic. Although the NMCP is the overall 
coordinating body for malaria interventions, the inclu-
sion of the RHD was vital since they are responsible for 
delivery of reproductive health services in the country 
including IPTp-SP. The importance of this collaboration 
can never be over-emphasised by the malaria in preg-
nancy working group meeting in Kenya, which attracted 
both NMCP and reproductive health MOH country rep-
resentatives to discuss the Roll Back Malaria guidelines 
for MIP [32]. Funding partners in the process played a 
major role through tracking progress and obtaining first-
hand reports.
Changing the policy was met with technical and 
administrative challenges that included the tedious pro-
cess of developing new IPTp-SP guidelines, bringing 
together all stakeholders in one place, and the cascade 
training of health workers which was adversely affected 
by change of per diem policy by the government. The 
previous per diem policy left room for public funds abuse 
when among other things events such as training work-
shop were conducted away requiring participants to 
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claim for some expenses not incurred and it was widely 
viewed as a method of supplementing one’s salary. The 
change in policy hence led to boycott of such events until 
resolutions were sought and one of the logistical issues 
was resolved by conducting training workshops in areas 
where most participants resided.
Nonetheless, many opportunities facilitated a smooth 
policy process. Most important was leadership by the 
MOH through the NMCP that showed keen interest in 
seeing the policy developed and implemented. Similarly, 
the NMCP was identified as critical in driving govern-
ment efforts in engaging and collaborating with the right 
stakeholders such as researchers in seeking evidence 
for policy formulation and its implementation [33]. It is 
important that the motivation emanates from the gov-
ernment if such a process is to be realized. Policy change 
in Timor-Leste that contained an escalation of malaria 
cases during a crisis was similarly supported and driven 
by government [34]. The use of WHO recommendations 
as motivation for policy change facilitated support from 
PMI, who provided technical and funding support to the 
process.
Conclusion
Malawi changed its IPTp policy based on the WHO rec-
ommendation in 2012. Research conducted in Malawi 
was instrumental in changing the global IPTp-SP policy 
due to the inclusion of findings in the systematic review 
that led to the WHO policy change. Malawi adapted and 
changed its IPTp-SP policy based on the resulting WHO 
recommendations. This change did not face many hur-
dles but was a welcome opportunity to address some of 
the challenges faced by health workers during implemen-
tation of the previous policy. The policy updating pro-
cess has highlighted the importance of commitment by 
the concerned government department to be motivated 
and drive the process. This should be accompanied by 
a thorough stakeholder analysis to identify and involve 
relevant key stakeholders from the initial stages of the 
policy change process. In addition, it is critical to utilize 
local evidence for this process and address current local 
health burdens leading to efficient public health care. The 
local evidence used in the process should be documented 
in the policy documents and guidelines for purposes of 
tracking research utilization and its impact.
Ideally, policymakers should use a framework that facil-
itates the use of malaria research to champion knowledge 
translation and work towards addressing the malaria 
burden in Malawi. Therefore, lessons from this study 
will inform the development of the malaria research-to-
policy framework in Malawi and the process of develop-
ing this framework can also advise the development of 
research-to-policy frameworks in other settings.
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